Su Manqiqige, Zhao Chongbo, Luo Sushan
Department of Neurology, Huashan hospital Fudan University, 200040 Shanghai, China.
Department of Neurology, Huashan hospital Fudan University, 200040 Shanghai, China.
Autoimmun Rev. 2022 Jan;21(1):102931. doi: 10.1016/j.autrev.2021.102931. Epub 2021 Sep 2.
Chimeric antigen receptor (CAR) based therapies have been adopted as an option for treating autoimmune diseases from the field of blood malignancies by targeting immune cells or rebalancing the pro-inflammatory milieu. Important questions still remained about the efficacy and safety regarding the dynamic and complex autoimmune pathological networks. We here reviewed the emerged developments in basic, translational, and clinical studies of the CAR based therapies in a wide spectrum of autoimmune diseases. The primary goal of the study is to provide some future perspectives on how to optimize the performance of CAR based therapies. The fundamental strategy is to engineer the recognition domains in CAR products for precisely targeting the components in the pro-inflammatory milieu. The second strategy is to incorporate multiple CARs in one carrier, or use fluorescein isothiocyanate (FITC)-CAR T cells for enhancing the therapeutic efficacy. In addition, we reviewed the preclinical evidence in disease-specific context. Overall, we aim to attract more attention in the field of developing future precision CAR based therapies to tailor medial decisions in autoimmune diseases.
基于嵌合抗原受体（CAR）的疗法已被用作一种治疗自身免疫性疾病的选择，它源自血液恶性肿瘤领域，通过靶向免疫细胞或重新平衡促炎环境来实现。关于动态且复杂的自身免疫病理网络，其疗效和安全性仍存在重要问题。我们在此回顾了基于CAR的疗法在广泛自身免疫性疾病的基础、转化和临床研究中出现的进展。该研究的主要目标是就如何优化基于CAR的疗法的性能提供一些未来展望。基本策略是对CAR产品中的识别域进行改造，以精确靶向促炎环境中的成分。第二种策略是在一个载体中整合多种CAR，或使用异硫氰酸荧光素（FITC）-CAR T细胞来提高治疗效果。此外，我们还回顾了疾病特异性背景下的临床前证据。总体而言，我们旨在吸引更多人关注未来基于CAR的精准疗法领域，以便为自身免疫性疾病的医疗决策提供依据。
